摘要
目的对ER和PR在滑膜肉瘤表达及与疾病临床病理特征和预后关系进行探讨。方法应用免疫组化EliVision两步法检测31例滑膜肉瘤标本ER和PR的表达。结果 31例滑膜肉瘤ER和/或PR表达有8例,阳性率25.8%(8/31例),其中ER阳性率87.5%(7/8例),PR阳性率50.0%(4/8例)。随访结果显示,ER和/或PR阳性组无瘤生存率为100.0%(6/6),ER和PR阴性组复发、转移或死亡率为66.7%(8/12),组间比较的差异有统计学意义(P<0.01);但两组间年龄、性别、部位及组织学分型无统计学差异(P>0.05)。结论 ER和/或PR阳性表达的滑膜肉瘤患者预后相对较好,提示ER及PR是滑膜肉瘤的一项重要预后指标,并有可能成为其内分泌治疗的重要依据;同时提示此类滑膜肉瘤可能具有向苗勒管来源肿瘤分化的特点。
Objective To observe the expression of ER and PR in synovial sarcoma,and to analyze the correlation between expression and the clinicopathological features and prognosis.Methods Immunohistochemistry was used to detect the expression of ER and PR in 31 cases of synovial sarcoma.Results In 31 cases of synovial sarcoma,the ER and（or）PR positive expression was observed in 8 patients,the positive rate was 25.8%（8/31）,thereinto the positive expression rate of the ER was 87.5%（7/8） and the PR was 50%（4/8）.Follow-up results showed the disease-free survival rate of ER and/or PR-positive group was 100%（6/6） and there were 8 patients with relapse,metastasis or death in the ER and PR-negative group that the rate was 66.7%（8/12）,the differences between the groups were statistically significant（P〈0.01）.However,there were no significant differences in age,gender,location and histological classification between tumors with and without ER/PR expression（P〉0.05）.Conclusion The prognosis of synovial sarcoma patients with positive expression of ER and/or PR is relatively good,which suggests ER and PR is an important prognostic indicator for synovial sarcoma and might become an important basis for endocrine therapy.While it is suggested that such synovial sarcoma may have the characteristics of differentiation from Muller tube tumor.
出处
《福建医药杂志》
CAS
2017年第4期81-83,共3页
Fujian Medical Journal
关键词
滑膜肉瘤
ER
PR
免疫组化
synovial sarcoma
ER
PR
Immunohistochemistry
